Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
Autor: | Tanya Michelle Jewell, Robert Steven Kania, Anand Sistla, Bennett Michael John, Michael R. Gehring, Evan Smith, Zehnder Luke Raymond, Shinji Yamazaki, Karen A. Maegley, Elena Z. Dovalsantos, Ben Burke, Fen Wang, Sacha Ninkovic, Jeff Wang, Joe Zhongxiang Zhou, Pei-Pei Kung, Min-Jean Yin, Michael J. Hickey, Martin James Wythes, Jerry Meng, Buwen Huang, Ping Kang, John F. Braganza, Ketan S. Gajiwala, Tatlock John H, Pramod P. Mehta |
---|---|
Rok vydání: | 2011 |
Předmět: | |
Zdroj: | Journal of Medicinal Chemistry. 54:3368-3385 |
ISSN: | 1520-4804 0022-2623 |
Popis: | A novel class of heat shock protein 90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application of medicinal chemistry principles. Through this process, the biochemical and cell-based potency of the original HTS lead were substantially improved along with the corresponding metabolic stability properties. These efforts culminated with the identification of a development candidate (compound 42) which displayed desired PK/PD relationships, significant efficacy in a melanoma A2058 xenograft tumor model, and attractive DMPK profiles. |
Databáze: | OpenAIRE |
Externí odkaz: |